



## PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM

### PRESS RELEASE

**Dr. Richard O'Reilly** is the third recipient of the Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMTc). Dr. O'Reilly is being recognized for a career that exemplifies the mission of the PBMTc, *"to support research and education to improve the availability, safety, and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents."*

Dr. O'Reilly is the chairman of the Department of Pediatrics at the Memorial Sloan-Kettering Cancer Center in New York. For over 30 years, he has dedicated his career to servicing the clinical, teaching and research missions of pediatric bone marrow transplantation and immunology. He received his medical training at the University Of Rochester School Of Medicine, and since then he has had positions in hospitals in Minnesota, Boston and New York. He introduced the use of unrelated HLA-matched transplants with Bo Dupont, John Hansen and Robert Good. Thereafter, he and Yair Reisner introduced T-cell depletion, demonstrating its potential to prevent graft vs. host disease following HLA-haplotype disparate parental transplants, and, in so doing, provided a curative approach for children with severe combined immunodeficiency who lack an HLA compatible donor. His studies of T-cell depleted transplants in children and adults with acute leukemias have established regimens that achieve consistent engraftment, and low rates of acute and chronic GVHD without post-transplant GVHD prophylaxis. In patients transplanted for ALL and AML, such grafts have not increased relapse risk. Using such grafts as a platform, he has introduced graded doses of DLI to treat relapsed CML in order to reduce GVHD risk, and was the first to demonstrate adoptive immunotherapy for EBV lymphomas. He is now focused on the development of practicable approaches for adoptive cell therapy for prevention and treatment of viral infections and leukemia posttransplant. Dr. O'Reilly has authored over 300 scientific publications and continues to participate in many organizations including the American Pediatric Society, the American Association of Immunologists and the American Society for Blood and Marrow Transplantation to name a few. His clinical research in immunology and bone marrow transplantation has advanced this field and improved the survival and quality of life of many patients undergoing this life-saving procedure.

The PBMTc is comprised of more than 100 pediatric BMT centers in the United States, Canada, New Zealand, Australia, with affiliate members in Europe, South America and Southeast Asia. The PBMTc is the largest clinical trials group focused exclusively on blood and marrow transplants for children and adolescents. Dr. O'Reilly will receive this well-deserved award during the 2011 Tandem BMT Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research to be held in Honolulu, Hawaii.



## PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM

The presentation of the award to Dr. O'Reilly will occur during the PBMTC Spring Meeting during the BMT Tandem Meetings in Honolulu, Hawaii. After receiving the award, Dr. O'Reilly will give a lecture outlining some of his achievements as well as a challenge to BMT community regarding important areas of future research. The presentation will take place on Friday, February 18, 2011 at 8:00 pm in room Moloka'i 315 of the Hawaii Convention Center. There is no cost to attend and dinner is provided. We invite friends, colleagues and all in the BMT community to attend and hear a thought-provoking lecture as we honor Dr. O'Reilly.

### References

1. O'Reilly, R.J., Dupont, B., Pahwa, S., Grimes, E., Smithwick, E.M., Pahwa, R., Schwartz, S., Hansen, J.A., Siegel, F.P., Sorell, M., Svejgaard, A., Jersild, C., Thomsen, M., Platz, P., L'Esperance, P., Good, R.A.: Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. *N. Engl. J. Med.*, 297: 1311-1318, 1977.
2. Reisner, Y., Kapoor, N., Kirkpatrick, D., Pollack, M.S., Dupont, B., Chaganti, R.S.K., Good, R.A., O'Reilly, R.J.: Transplantation for acute leukemia with HLA-A & B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. *Lancet*, 2: 327-331, 1981.
3. Reisner, Y., Kapoor, N., Kirkpatrick, D., Pollack, M.S., Cunningham-Rundles, S., Dupont, B., Hodes, M.Z., Good, R.A., O'Reilly, R.J.: Transplantation for severe combined immunodeficiency with HLA-A, B, D, Dr incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. *Blood*, 61: 341-348, 1983.
4. Brochstein, J., Kernan, N.A., Groshen, S., Cirrincione, C., Shank, B., Emanuel, D., Laver, J., O'Reilly, R.J.: Allogeneic bone marrow transplantation following hyperfractionated total body irradiation and cyclophosphamide for children with acute leukemia. *N. Engl. J. Med.*, 317: 1618-1624, 1987.
5. Kernan, N.A., Flomenberg, N., Dupont, B., O'Reilly, R.J.: Graft rejection in recipients of T cell depleted HLA non-identical marrow transplants for leukemia: Identification of host derived anti-donor alloctyotoxic T-lymphocytes. *Transplantation*, 43: 842-847, 1987.]
6. Young, J.W., Papadopoulos, E., Cunningham, I., Castro-Malaspina, H., Flomenberg, N., Carabasi, M.H., Gulati, S.C., Brochstein, J.A., Heller, G., Black, P., Collins, N.H., Shank, B., Kernan, N.A., O'Reilly, R.J.: T cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. *Blood*, 79: 3380-3387, 1992.
7. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, Gillio F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O'Reilly RJ, Young JW: T cell-depleted allogeneic bone marrow transplantation as post-remission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-vs-host disease. *Blood* 91:3, 1083-90, 1998.



## PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM

8. Jakubowski AA, Small TN, Young JW, Kernan NA, Perales MA, Castro-Malaspina, Hsu K, Collins N, Chiu M, van den Brink M, O'Reilly RJ, Papadopoulos. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007 Dec 15;110(13):4552-9.
9. Mackinnon, S., Papadopoulos, E.B., Carabasi, M.H., Reich, L., Collins, N.H., Boulad, F., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Kernan, N.A., Small, T.N., Young, J.W. and O'Reilly, R.J.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: separation of Graft-versus-Host leukemia responses from Graft-versus-Host disease. Blood, 86 (4) 1261-1268, 1995.
10. Papadopoulos, E., Ladanyi, M., Emanuel, D., Mackinnon, S., Rosenfield, N., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., Young, J.W., Kernan, K.A., O'Reilly, R.J.: Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. New England Journal of Medicine, 330: 1185-1191, 1994.
11. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of cytomegalovirus (CMV)-specific T-lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. April 1 105 (7): 2793-2801, 2005.
12. Doubrovina ES, Doubrovin MM, Lee S, Shieh JH, Heller G, Pamer E, O'Reilly RJ. *In vitro* stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide –specific T cells with *in vitro* tumoricidal activity. Clinical Cancer Research. Nov 1;10(21):7207-7219, 2004.
13. Hasan A, Kollen W, Trivedi D, Selvakumar A, Dupont B, Sadelain M, O'Reilly. A panel of artificial antigen presenting cells expressing prevalent HLA alleles permits generation of CMV-specific cytotoxic T-cells of desired HLA restriction for adoptive cell therapy. J Immunol. 2009 Aug 15;183(4):2837-50.
14. Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, et al. T-cell depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2011 Jan 10 (Epub ahead of print).